High rates of antipsychotic and benzodiazepine prescribing in residential aged care facilities (RACFs) has been well documented. A recent study concluded that only 10% of psychotropic agents prescribed for RACF residents with dementia were completely appropriate, particularly with respect to indication and therapy duration.

Significant reductions in the proportion of residents prescribed antipsychotics and benzodiazepines has been shown through the Reducing Use of Sedatives (RedUSe) study. Targeted interventions comprising psychotropic medication audit and feedback, staff education, and interdisciplinary medication reviews reduced use, without any increase in as-needed (prn) prescribing of psychotropic drugs.

The Department of Health has recently released a quick reference infographic outlining the 6 steps for safe prescribing of antipsychotics and benzodiazepines in residential aged care.

BPSD

Behavioural and psychological symptoms of dementia (BPSD) is a commonest complication of dementia, including Alzheimer’s disease. Symptoms will vary considerably between persons and may fluctuate or escalate over time. The variety of symptoms can be grouped into 3 clusters:

- Depression, withdrawal, adynamia (lack of strength or vigor), amotivation, anhedonia (loss of interest in normally pleasurable activities), tearfulness, hopelessness, ruminations
- Delusions, hallucinations, misidentifications, perseverations, bizarre behaviour, agitation and anxiety
- Aggression (verbal/physical), restiveness (impatient or hard to control), wandering, intrusiveness, inappropriate urinating, sexualised behaviours, disrobing, shadowing, calling out, sleep disturbance

Medications

Many different medicines have been used for managing BPSD. There is limited evidence for antipsychotics, antidepressants, benzodiazepines, anticonvulsants, hormonal treatments, cholinesterase inhibitors and memantine. Choice of therapy should be guided by the resident’s presenting symptoms. Hallucinations and delusions are likely to be responsive to antipsychotics. Behaviours such as wandering, undressing, urinating inappropriately, shadowing staff or calling out are unlikely to respond the drug therapy, and use of these medicines for this purpose may constitute chemical restraint. Anxiolytics such as benzodiazepines may be beneficial for short-term management of agitation and anxiety.

Risperidone is the only atypical antipsychotic subsidised on the PBS for the treatment of psychotic symptoms and aggression. Since 2015, the approved duration of treatment has been limited to 12 weeks. From January this year, the PBS listing changed again with the aim to reduce inappropriate prescribing, specifically beyond 12 weeks of therapy. The requirement to request authority approval for PBS-subsidised therapy beyond 12 weeks is intended to prompt trial dose reduction or cessation. Antipsychotic drugs are associated with increased risks of falls, stroke and death. Other adverse effects include extrapyramidal symptoms, constipation, dry eyes, dry mouth, confusion and drowsiness. Benzodiazepines are associated with increased risks of falls, pneumonia and death, especially in higher doses and longer duration of use.

Combinations of psychotropic medicines in older people are associated with a risk of falls and hip fracture. Antidepressants, opioids, antiepileptic drugs, benzodiazepines and antipsychotics all increase the risk of hip fracture. The highest risk of hip fracture is when a benzodiazepine and an SSRI antidepressant are started together; a common combination used to treat anxiety and depression.

6 steps for safe prescribing

The Department of Health infographic details 6 steps for safe prescribing of antipsychotics and benzodiazepines to manage the behavioural and psychological symptoms of dementia. A key message is that prescribing antipsychotics or benzodiazepines should be the exception, not the norm.
In general, benzodiazepines and Z-drugs (zopiclone, zolpidem) can be successfully weaned by 25% of the daily dose every 1 to 4 weeks. Slower weaning may be necessary when reducing to the final lowest dose. The Therapeutic Guidelines (eTG) recommends stabilisation on an equivalent dose of diazepam (Valium) for people taking high dose benzodiazepines. eTG includes a table of comparative oral doses of benzodiazepines; for example, 0.5mg alprazolam and 15mg oxazepam are equivalent to 5mg diazepam. Common symptoms of benzodiazepine withdrawal include anxiety, insomnia, irritability, myoclonic jerks, palpitations, and sensory disturbances. Abrupt discontinuation of high doses may cause seizures.

Summary

Antipsychotics should not be used as the first choice to treat behavioural and psychological symptoms of dementia. Benzodiazepines and other sedative/hypnotics should not be prescribed as first choice for insomnia, agitation or delirium. Antipsychotics and benzodiazepines should not be continued for more than 3 months without a review. Non-pharmacological management is the first-line treatment option for BPSD.

Resources


NPS MedicineWise resources: https://www.nps.org.au/professionals/antipsychotic-medicines

References

Int Psychogeriatr 2016;28:1589-95.

The Webstercare Consultant Pharmacist Continuing Education Service came to you each month from your pharmacist. If you would like extra copies please visit www.webstercare.com.au or ask your pharmacist.